The Latest Breaking News from Wegovy

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

The weight-loss journey for a growing number of Australians using "miracle" medications must include exercise or risk long-term health problems, experts warn.

Novo Nordisk A/S (NYSE:NVO) may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals.

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3…

Darren Ratcliffe was paying £270 a month for weight-loss jab Mounjaro

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday.

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand.